StimCell Engages Stonegate Capital Markets
Analysis based on 7 articles · First reported Sep 08, 2026 · Last updated Sep 08, 2026
The agreement is a modest positive for StimCell as it may facilitate future capital raising and strategic transactions, potentially supporting its growth initiatives. For Stonegate, the engagement represents a new client relationship with potential success-based fees, though no immediate financial impact is expected.
StimCell Energetics Inc., a biotech company focused on cellular energy and wellness products, announced on September 8, 2026, that it has entered into an Advisory Services Agreement with Stonegate Capital Partners, Inc., effective August 24, 2026. Under the agreement, Stonegate will act as a non-exclusive advisor on a best-efforts basis to identify and introduce prospective investors and strategic counterparties for potential transactions involving StimCell's assets, property, rights, debt, or equity securities. All transactions remain subject to StimCell's approval. Stonegate will receive a success-based advisory fee as a percentage of gross proceeds from any completed transaction involving its contacts, payable upon closing. The agreement has an initial three-month term and may be terminated by either party with 30 days' written notice. Any securities offering is expected to be structured under Rule 506(c) of Regulation D. This engagement is separate from StimCell's previously announced arrangement with Stonegate Capital Partners, Inc. for research coverage and institutional investor outreach.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard